Spectranetics receives CE mark for Stellarex 0.014 drug-coated balloon

748
Covidien Stellarex Drug-Coated Angioplasty Balloon
Stellarex

Spectranetics’ Stellarex 0.014” drug-coated angioplasty balloon has received the CE mark.

The Stellarex 0.014” device is designed to treat small vessels, below-the-knee disease, and challenging critical limb ischaemia.

“Now available on a 0.014” balloon platform, Stellarex represents a latest-generation drug-coated balloon backed by compelling evidence in the fem-pop arteries. It holds strong promise to deliver safety and efficacy in the notoriously challenging infrapopliteal district,” says Dierk Scheinert of Universitätsklinikum in Leipzig, Germany.